A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer.
Publication/Presentation Date
1-1-2025
Volume
21
Issue
2
First Page
169
Last Page
179
ISSN
1744-8301
Published In/Presented At
Waguespack, S. G., Cabanillas, M. E., Bernard-Gauthier, V., Assar, N., Bloom, G., Esparza, R., & Brose, M. S. (2025). A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer. Future oncology (London, England), 21(2), 169–179. https://doi.org/10.1080/14796694.2024.2415208
Disciplines
Medicine and Health Sciences
PubMedID
39614411
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS